

# Press Release

Abliva AB (publ), 556595-6538  
29 May 2020 08:30:00 CEST - Lund,  
Sweden



---

## Amended number of shares and votes in Abliva AB (publ)

**Abliva AB (Nasdaq Stockholm: ABLI) today announced an increase of the number of shares and votes in Abliva of 83,720,875 as a result of a fully performed preferential rights issue, resolved by the Board of Directors on 19 February 2020 and approved at the Extraordinary General Meeting on 17 March 2020.**

Today, the last trading day of the month, there are in total 269,673,466 shares and votes in Abliva AB.

*This information is information that Abliva AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2020-05-29 08:30 CEST.*

**For more information, please contact:**

---

Catharina Johansson, CFO, IR & Communications  
+46 (0)46-275 62 21, [ir@abliva.com](mailto:ir@abliva.com)

### **Abliva AB (publ)**

Medicon Village, SE-223 81 Lund, Sweden  
Tel: +46 (0)46 275 62 20 (switchboard)  
[info@abliva.com](mailto:info@abliva.com), [www.abliva.com](http://www.abliva.com)

Follow us on LinkedIn: <https://www.linkedin.com/company/abliva>  
Subscribe to our YouTube channel: <https://www.youtube.com/channel/UCChqP7Ky5caXtp72CELhD6Mg>

### **About Us**

---

Abliva AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects. Abliva's ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under the NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber's Hereditary Optic Neuropathy (LHON). Abliva is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

### **Attachments**

---

[Amended number of shares and votes in Abliva AB \(publ\)](#)

**Abliva AB (publ)** - the mitochondrial medicine company. The company is listed on Nasdaq Stockholm, Small Cap, under the ticker symbol ABLI.

# Press Release

Abliva AB (publ), 556595-6538  
29 May 2020 08:30:00 CEST - Lund,  
Sweden

---

The logo for Abliva AB, featuring the word "ABLIVA" in a bold, dark teal, sans-serif font. The letters are closely spaced and have a slightly irregular, hand-drawn appearance.